A carregar...
Reversing the curse on PPARγ
Thiazolidinediones (TZDs) are the only antidiabetic drugs that reverse insulin resistance. They have been a valuable asset in the treatment of type 2 diabetes, but their side effects have curtailed widespread use in the clinic. In this issue of the JCI, Kraakman and colleagues provide evidence that...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983334/ https://ncbi.nlm.nih.gov/pubmed/29757190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI121392 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|